Rolf Bjerkvig (f. 1953) is Professor for cell biology and has since the ealy 80s worked in experimental cancer biology.
Bjerkvig is Director of the Kristian Gerhard Jebsen Brain Tumor Research Center, located at the Department of Biomedicine. He is director of the Oncology Department at the Luxembourg Institute of Health, and has established the NORLUX Neuro-Oncology network.
Dr Bjerkvig receives major grants from the Norwegian Research Council, The Norwegian Cancer Society and the European Commission. He is on the editorial board on several international journals and is sitting in several national as well as international funding committees for cancer research in Europe. He has published more than 200 articles in scientific literature and has received a number of research prizes for his work. In 2015, Bjerkvig was awarded the King Olav V Research Prize in Cancer Research.
- 2017. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Journal of Experimental & Clinical Cancer Research. 36:106: 1-15. doi: 10.1186/s13046-017-0577-2
- 2017. The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors. Nature Communications. 8:1571: 1-20. doi: 10.1038/s41467-017-01686-y
- 2017. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro-Oncology. 20: 743-752. doi: 10.1093/neuonc/nox191
- 2017. Altered metabolic landscape in IDH‐mutant gliomas affects phospholipid, energy, and oxidative stress pathways. EMBO Molecular Medicine. 9: 1681-1695. doi: 10.15252/emmm.201707729
- 2017. Lack of functional normalisation of blood vessels following anti-angiogenic therapy in glioblastoma. Journal of Cerebral Blood Flow and Metabolism. doi: 10.1177/0271678X17714656
- 2017. Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7. Experimental Cell Research. 356: 64-73. doi: 10.1016/j.yexcr.2017.04.013
- 2017. The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro-Oncology. 19: 383-393. doi: 10.1093/neuonc/now175
- 2017. Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination. Journal of Experimental & Clinical Cancer Research. 36:118: 1-13. doi: 10.1186/s13046-017-0588-z
- 2017. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy. OncoTarget. 8: 12145-12157. doi: 10.18632/oncotarget.14553
- 2016. Experimental therapies: gene therapies and oncolytic viruses. Chapter 11, pages 183-197. In:
- 2016. Gliomas. Elsevier. 446 pages. ISBN: 978-0-12-802997-8.
1987: Dr. philos. The Gade Institute of Pathology, University of Bergen
1981: M.Sc. Immunology, University of San Francisco, 1981.